In the case of MLL fusion-mediated leukemia, MLL fusion proteins directly activate both MYC and HOXA9, while HOXA9 maintains expression of MYC, BCL2, and SOX4, achieving high MYC activity and anti-apoptotic properties simultaneously (Figure 7E). Here, KMT2A is linked to leukemia.